Suchen
Redhill Biopharma Ltd
RDHLZur Watchlist hinzufügen
0.635USD
+0.005+0.76%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
3.24MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Redhill Biopharma Ltd Unternehmen
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd Informationen
BörsenkürzelRDHL
Name des UnternehmensRedhill Biopharma Ltd
IPO-datumFeb 01, 2011
CEOBen-Asher (Dror)
Anzahl der mitarbeiter35
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 01
Addresse21 Ha'arba'a St.
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6473921
Telefon97235413131
Websitehttps://www.redhillbio.com/
BörsenkürzelRDHL
IPO-datumFeb 01, 2011
CEOBen-Asher (Dror)
Führungskräfte von Redhill Biopharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Redhill Biopharma Ltd?
Die fünf größten Anteilseigner von Redhill Biopharma Ltd sind: Mr. Dror Ben-Asher
Wie viele Institutionen halten Anteile an Redhill Biopharma Ltd (RDHL)?
Mit Stand vom 2026Q1 halten 36 Institutionen Anteile an Redhill Biopharma Ltd, mit einem Gesamtmarktwert von etwa 504.44K, was 9.72% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 347269.00 gestiegen.